SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: wvalx who wrote (21025)4/21/1999 5:25:00 PM
From: Little Gorilla  Respond to of 23519
 
>>They are probably going to increase R+D to wipe out any profit, which I say is a very wise decision.<<

That's what I think too.



To: wvalx who wrote (21025)4/21/1999 5:28:00 PM
From: Mkilloran  Respond to of 23519
 
Wvalx,,,,don't be shocked if they start testing the Female SD product as well this year...more R&D expenses along with the testing of pre-mature Ejack testing and the expense to file the NDA for Alibra....

Key point MUSE and ALIBRA will be the cash engine to fund the R&D pipeline with product that has much more potential than MUSE and Alibra......


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News